The figure shows homologous recombination repair marker, RAD51 (red), in high-grade serous ovarian cancer tumor cell nuclei (blue).
The figure shows homologous recombination repair marker, RAD51 (red), in high-grade serous ovarian cancer tumor cell nuclei (blue).

New tool for tailoring drug treatment in ovarian cancer

Researchers at the Universities of Helsinki and Turku have developed a test to identify those ovarian cancer patients who benefit from traditional platinum-based chemotherapy as well as from a newer…

Continue ReadingNew tool for tailoring drug treatment in ovarian cancer

New subprojects initiating in the iCAN Flagship Project

The iCAN Flagship Project has taken tremendous steps in 2022 with establishment of the pipeline for prospective sample collection and molecular profiling and establishment of the iCAN Discovery Platform where data analysis takes place in a safe environment. With the turn of the year another big change is taking place with initiation of the 2nd term of the Flagship Project with refined overall objectives and new host subprojects.

Continue ReadingNew subprojects initiating in the iCAN Flagship Project